anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Anti-perspirant compostions comprising an active anti-perspirant agent suspended in a readily collapsible foam, contain with this agent, a non-volatile non-toxic cosmetic carrier, a volatile solvent, water and a liquefied normally gaseous propellant.  The propellant may be a fluorinated chlorohydrocarbon, propane or isobutane, and the volatile solvent is preferably a volatile alcohol such as ethanol or isobutanol. Anti-perspirant agents are aluminium salts, such as the chloride, sulphate, chlorhydroxide (chlorhydrate, or chlorhydroxyallantoinate. Non-volatile carriers may be one or more of propylene glycol, diethylene glycol, stearic acid, cetyl alcohol, lanolin derivatives, polyoxyethylene ethers and esters, magnesium aluminium silicate gel, stearyl alcohol, isopropyl myristate and glycerol.  The compositions may contain allantoin.ALSO:Anti-perspirant compositions comprising an active anti-perspirant agent suspended in a readily collapsible foam contain with the said agent, a non-volatile non-toxic cosmetic carrier, a volatile solvent, water and a liquefied normally gaseous propellant. Anti-perspirant agents may be aluminium sulphate; aluminium chlorhydroxide (chlorhydrate); aluminium chloride; or aluminium chlorhydroxy allantoinate.  Non-volatile carriers may be one or more of propylene glycol, stearic acid, cetyl alcohol, lanolin derivatives, polyoxyethylene ethers and esters, magnesium aluminium silicate gel, stearyl alcohol, isopropyl myristate, glycerol, and diethylene glycol.  The volatile solvent is preferably a volatile alcohol such as ethanol or isopropanol.  The propellant may be a fluorinated hydrocarbon, propane or isobutane.  The compositions may also contain allantoin.  They form a penetrating foam intended to leave no residue or wet condition on application to the skin.
OBJECTIVE: This study aimed to report the long-term outcomes beyond 10 years of endovascular aneurysm repair (EVAR) for abdominal aortic aneurysms using the low-profile INCRAFT device.
METHODS: This was a single-center, retrospective cohort study of all patients undergoing EVAR using the INCRAFT device as part of the regulatory trial between 2012 and 2013. Primary endpoint was aneurysm-related death. Secondary endpoints were all-cause death, reintervention, late open conversion, and aneurysm status (shrinkage, stable, and growth).
RESULTS: Thirty patients with a mean age of 71.8 ± 7.7 years were included in this study. The median aneurysm diameter at EVAR was 54.5 mm (interquartile range, 53-56.8 mm). All abdominal aortic aneurysms in this study were treated following the device's instructions for use. At index EVAR, the INCRAFT device was successfully implanted in all patients using a percutaneous approach under local anesthesia. No patients experienced major adverse events or procedure-related complications 30 days after EVAR. During the median follow-up of 125 months (interquartile range, 98-131 months) with follow-up rates of 100% at 5 years and 96.7% at 10 years, aneurysm-related mortality was 0%, and freedom from all-cause mortality was 82.9% at 5 years and 75.3% at 10 years. Reintervention was required in 10 patients with 15 procedures. Sac growth was observed in 11 patients (36.7%), six of whom eventually required late open conversion; five of these patients underwent open aneurysmorrhaphy with stent graft preservation, and one underwent open surgical repair with endograft explantation. Late rupture was identified in one case, where type Ia endoleak led to rupture at 69 months, and open repair was successfully performed. Freedom from reintervention was 89.0% at 5 years but declined to 60.9% at 10 years; freedom from late open conversion was 100% at 5 years but declined to 70.8% at 10 years.
CONCLUSIONS: Long-term outcomes of the INCRAFT stent graft showed no aneurysm-related deaths. However, sac growth occurred persistently throughout the follow-up period, resulting in a relatively high rate of reinterventions in the later periods, which highlights the importance of lifelong postoperative surveillance and appropriate reinterventions when indicated.
In this study, it was aimed to evaluate the independent risk factors for osteomyelitis, amputation and major amputation of the diabetic foot infection in the forward direction without using standard scoring procedures. Patients who were applied to Diabetic Foot Council of our setting with diabetic foot infections between 2012 and 2014 were included in the study. Patients were followed prospectively and ethical approval was obtained from research ethics committee of our setting. An informed consent form was provided by each patient. Diabetic foot infection was decided as local infection involving only the skin and the subcutaneous tissue or infection involving symptoms and signs more than this criterion. Properties and variables of the cases were recorded during the admission process with total 57 different situations. The related characteristics were followed until the end of the treatment. Osteomyelitis, amputation and factors affecting to have major amputation on the cases were investigated. In the first step, data normality tests were performed with a simple data analysis and univariate analysis was applied in the second stage to which meaningful. At the last stage, major amputation, amputation and osteomyelitis were analyzed with stepwise multiple logistic analysis (SLA) model. Logistic regression was subject as significant data were saved as the independent risk factor. The Odds ratio and 95% CI were calculated from the beta coefficients of the variables with significant p value. P \< 0.05 was used for significance at all tests.
Background: Laparoscopic sac disconnection and peritoneal closure represents an alternative to open pediatric hernia repair. We performed a retrospective review of our data to evaluate this alternative method. Materials and Methods: With REB approval, a retrospective chart review of all patients who underwent laparoscopic indirect inguinal hernia repair between June 2013 and July 2016 was conducted. Primary outcome was the recurrence rate. Secondary outcomes included length of surgery, postoperative hydrocele, and perioperative complications. Data were extracted from EPIC Hyperspace onto a standardized data extraction form. Results: A total of 243 patients were included, of which 82% were males. Age ranged from 1 month to 17 years of age. A total of 322 defects were repaired. Eighty (32%) had contralateral patent processus vaginalis. Twelve (4%) patients presented with incarceration and three (1.2%) had a direct inguinal hernia defect. Recurrence rate was 0.6% (n = 2). There were no intraoperative complications. Operative time was an average of 40 and 54 minutes for unilateral and bilateral repairs, respectively. No testicular ascents, testicular atrophy, vas deferens injury, postoperative hydroceles, and wound infections were reported. Conclusion: Laparoscopic sac disconnection and peritoneal closure of pediatric inguinal hernia is a safe, feasible method with one of the lowest reported recurrence rate among the other laparoscopic methods.
STUDY OBJECTIVES: Automatic sleep staging based on cardiorespiratory signals from home sleep monitoring devices holds great clinical potential. Using state-of-the-art machine learning, promising performance has been reached in patients with sleep disorders. However, it is unknown whether performance would hold in individuals with potentially altered autonomic physiology, for example under the influence of medication. Here, we assess an existing sleep staging algorithm in patients with sleep disorders with and without the use of beta blockers.
METHODS: We analyzed a retrospective dataset of sleep recordings of 57 patients with sleep disorders using beta blockers and 57 age-matched patients with sleep disorders not using beta blockers. Sleep stages were automatically scored based on electrocardiography and respiratory effort from a thoracic belt, using a previously developed machine-learning algorithm (CReSS algorithm). For both patient groups, sleep stages classified by the model were compared to gold standard manual polysomnography scoring using epoch-by-epoch agreement. Additionally, for both groups, overall sleep parameters were calculated and compared between the two scoring methods.
RESULTS: Substantial agreement was achieved for four-class sleep staging in both patient groups (beta blockers: kappa = 0.635, accuracy = 78.1%; controls: kappa = 0.660, accuracy = 78.8%). No statistical difference in epoch-by-epoch agreement was found between the two groups. Additionally, the groups did not differ on agreement of derived sleep parameters.
CONCLUSIONS: We showed that the performance of the CReSS algorithm is not deteriorated in patients using beta blockers. Results do not indicate a fundamental limitation in leveraging autonomic characteristics to obtain a surrogate measure of sleep in this clinically relevant population.
CITATION: Hermans L, van Meulen F, Anderer P, et al. Performance of cardiorespiratory-based sleep staging in patients using beta blockers. J Clin Sleep Med. 2024;20(4):575-581.
In their ICSI cycle patients will take 0.25 mg of cabergoline daily for 8 days from HCG triggering day to prevent OHSS. Early OHSS is assessed at day of embryo transfer and 7 days after this date. Late OHSS is assessed 14 days after embryo transfer.
Sex differences in the in-hospital management of sepsis exist. Previous studies either included patients with sepsis that was defined using previous definitions of sepsis or evaluated the 3-h bundle therapy. Therefore, this study sought to assess sex differences in 1-h bundle therapy and in-hospital management among patients with sepsis and septic shock, defined according to the Sepsis-3 definitions. This observational study used data from Korean Shock Society (KoSS) registry, a prospective multicenter sepsis registry. Adult patients with sepsis between June 2018 and December 2021 were included in this study. The primary outcome was adherence to 1-h bundle therapy. Propensity score matching (PSM) and multivariable logistic regression analyses were performed. Among 3264 patients with sepsis, 3129 were analyzed. PSM yielded 2380 matched patients (1190 men and 1190 women). After PSM, 1-h bundle therapy was performed less frequently in women than in men (13.0% vs. 19.2%; p < 0.001). Among the bundle therapy components, broad-spectrum antibiotics were administered less frequently in women than in men (25.4% vs. 31.6%, p < 0.001), whereas adequate fluid resuscitation was performed more frequently in women than in men (96.8% vs. 95.0%, p = 0.029). In multivariable logistic regression analysis, 1-h bundle therapy was performed less frequently in women than in men [adjusted odds ratio (aOR) 1.559; 95% confidence interval (CI) 1.245-1.951; p < 0.001] after adjustment. Among the bundle therapy components, broad-spectrum antibiotics were administered less frequently to women than men (aOR 1.339, 95% CI 1.118-1.605; p = 0.002), whereas adequate fluid resuscitation was performed more frequently for women than for men (aOR 0.629, 95% CI 0.413-0.959; p = 0.031). Invasive arterial blood pressure monitoring was performed less frequently in women than in men. Resuscitation fluid, vasopressor, steroid, central-line insertion, ICU admission, length of stay in the emergency department, mechanical ventilator use, and renal replacement therapy use were comparable for both the sexes. Among patients with sepsis and septic shock, 1-h bundle therapy was performed less frequently in women than in men. Continuous efforts are required to increase adherence to the 1-h bundle therapy and to decrease sex differences in the in-hospital management of patients with sepsis and septic shock.
The invention provides an animal diarrhea-resistant animal combined lactobacillus ZJUIDS-R2 and application thereof. The animal combined lactobacillus ZJUIDS-R2 (Ligilactobacillus animalis) is deposited as follows: CGMCC NO. 2460. The animal combined lactobacillus ZJUIDS-R2 with the diarrhea preventing function is screened from probiotics separated from healthy pet rabbit dung. The strain has strong bile salt hydrolase activity, has obvious advantages in acid resistance and bile salt resistance compared with other lactic acid bacteria, is suitable for gastrointestinal environment and has proliferation capacity. The strain has no antibiotic resistance, has antibacterial activity, and can inhibit intestinal harmful pathogenic bacteria. The animal combined with lactobacillus ZJUIDS-R2 can be applied to the preparation of products for preventing pet diarrhea. The animal combined lactobacillus in the invention can be widely used for developing diarrhea prevention related probiotic functional products.
Cell death frequently occurs in the pathogenesis of obesity and metabolic dysfunction-associated fatty liver disease (MAFLD). However, the exact contribution of core cell death machinery to disease manifestations remains ill-defined. Here, we show via the direct comparison of mice genetically deficient in the essential necroptotic regulators, receptor-interacting protein kinase-3 (RIPK3) and mixed lineage kinase domain-like (MLKL), as well as mice lacking apoptotic caspase-8 in myeloid cells combined with RIPK3 loss, that RIPK3/caspase-8 signaling regulates macrophage inflammatory responses and drives adipose tissue inflammation and MAFLD upon high-fat diet feeding. In contrast, MLKL, divergent to RIPK3, contributes to both obesity and MAFLD in a manner largely independent of inflammation. We also uncover that MLKL regulates the expression of molecules involved in lipid uptake, transport, and metabolism, and congruent with this, we discover a shift in the hepatic lipidome upon MLKL deletion. Collectively, these findings highlight MLKL as an attractive therapeutic target to combat the growing obesity pandemic and metabolic disease.
Children with recent positive SARS-CoV-2 PCR test (nasopharyngeal swab). Will consist of asymptomatic children that are admitted to the Children's Hospital for reasons other than COVID-19 and symptomatic children.
Successive cohorts of 16 participants consisting of 8 non-Japanese and 8 Japanese (12 ASP7713/ 4 Placebo /1-3 cohorts) will each be started on a fixed multiple dose of ASP7713 or matching Placebo twice or three times daily for 14 days. Safety, tolerability and available Pharmacokinetic data from proceeding cohorts will be assessed for dose escalation.
Subjects will be male and female, 18 to 75 years old, with Type 2 diabetes mellitus, a documented or suspected history of coronary artery disease, and a Haptoglobin type 2-2 (Hp 2-2) genotype. Subjects on prescribed anti-diabetic and coronary artery disease medications may continue to take their medications throughout the study.

Subjects who qualify will receive active drug (ALT-2074 20 mg, 40 mg or 80 mg) or placebo every 8 hours for 28 days. There will be three sequential cohorts of increasing doses of active drug. There will be 2 follow-up visits (Days 35 and 42). Blood and urine tests for safety (chemistry and hematology), pharmacokinetics and relevant biomarkers to measure inflammation and oxidative stress will be performed throughout the study. Electrocardiograms and 24-hour Holter monitoring will also be performed at various time points during the study.
PURPOSE:To provide a complement activity inhibiting agent containing zinc ion as an active component, inhibiting the activation of the complement first path based on the antigen and antibody composite and the complement second path occurring in the absence of antibody, effective for the remedy of autoimmune diseases, and having low toxicity. CONSTITUTION:The objective complement activity inhibiting agent is produced by using zinc ion as an active component. It has been found that zinc ion (Zn<2+>) has excellent complement activity inhibiting effect, and is useful as a complement activity inhibiting agent. The zinc ion formed by the administration of a zinc compound (e.g. zinc chloride, zinc phosphate, zinc acetate, glycine zinc, etc.) inhibits the formation of both C3 convertase (C142 and C3b, Bp, P) playing the most important role in the activation of a complement. The complement activity inhibiting effect of zinc ion takes place through the complement controlling mechanism inherent to a living body. It is useful for the remedy of autoimmune diseases such as glomerulonephritis, etc., and drug allergy.
1. Technical Result Increase in concentrate stability.         2. Essence The present invention provides an essentially nonaqueous, liquid pharmaceutical concentrate composition for oral administration containing sertraline or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients. The concentrate is used to treat or prevent a variety of diseases or conditions. Finally, the present invention provides the compound, (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine methanesulfonate.         3. Field of Application Medicine.
PURPOSE: The medial approach to the popliteal artery has been less commonly used than the posterior approach in surgical repair of traumatic popliteal injury. This study was performed to quantitatively evaluate the visual field of the popliteal artery obtained by staged myotendotomy in the medial approach to the popliteal artery.
METHODS: Twenty legs of fresh-frozen adult cadavers were dissected using the medial approach to the popliteal artery. In stage 1, the popliteal artery was exposed between the vastus medialis and sartorius muscles without myotendotomy. In stage 2, the medial head of the gastrocnemius muscle was dissected. In stage 3, the tendons of the sartorius and semimembranosus muscles were dissected. In stage 4, the tendons of the gracilis and semitendinosus muscles were dissected to fully expose the popliteal artery. The length of the popliteal artery that could be visualized in each stage was measured.
RESULTS: The anatomical length of the popliteal artery from the hiatus of the adductor magnus to the tendinous arch of soleus muscle ranged from 15 to 20 cm (mean, 16.3 cm). On average, 45%, 59%, 72%, and 100% of the popliteal artery were visualized in stage 1, 2, 3, and 4, respectively.
CONCLUSIONS: The medial approach to the popliteal artery has the advantage of being performed in the supine position, but it requires multiple myotendotomies around the knee. The results of this study may serve as a reference for myotendotomy depending on the site of injury to the popliteal artery.
Cohort E2 will involve an expansion to evaluate atezolizumab administered in combination with daratumumab and the maximum tolerated dose (MTD) of lenalidomide determined in Cohort E1 in participants with relapsed or refractory MM who have received up to 3 lines of prior treatment. NOTE: This cohort is closed to enrollment.
BACKGROUND: Endoscopic thyroidectomy has been preliminarily proven effective and safe for thyroid diseases. The cosmetic outcomes and life quality are critical contents of postoperative assessment. This review will primarily focus on the assessment methods and results related to cosmetic outcomes, sensory alteration of surgical area, and quality of life following endoscopic thyroidectomy.
METHODS: A comprehensive search of published articles within the last decade was conducted using the terms "endoscopic/robotic thyroidectomy," "patient satisfaction scores," "questionnaire," "quality of life," and "cosmetic" in PubMed.
RESULTS: Assessment methods for postoperative cosmetic satisfaction and sensory alterations encompassed verbal/visual analog scales, scar evaluations, Semmes-Weinstein monofilament tests, and more. The evaluation of postoperative quality of life in endoscopic thyroidectomy involved tools such as SF-36, SF-12, thyroid-specific questionnaires, thyroid cancer-specific quality of life questionnaires (THYCA-QOL), as well as assessments related to voice and swallow function. The cosmetic results of endoscopic thyroidectomy generally surpassed those of open thyroidectomy, while the quality of life in endoscopic procedures was either superior or equivalent to that in open thyroidectomy, especially with respect to general health, role emotion, and vitality.
CONCLUSIONS: Assessments of cosmetic outcomes and sensory alterations following endoscopic thyroidectomy predominantly relied on patients' subjective feelings. The objective and subjective perspectives of scar assessments remain underutilized. In addition, postoperative laryngoscopy and voice function assessments in endoscopic thyroidectomy procedures require more attention.
The invention provides application of salvianolate in preparation of kidney protective agent drugs. A study on effects of injection-use salvianolate on acute myocardial perfusion in acute myocardial infarction direct PCI (percutaneous coronary intervention) and prognosis founds that: subjects using the injection-use salvianolate, compared with other group subjects, after use of a contrast agent, may not have severe kidney injuries, and the injection-use salvianolate has a kidney protective effect. The invention also provides the application of magnesium lithospermate B in preparation of the kidney protective agent drugs. Effects of the magnesium lithospermate B on kidney microcirculation and overall hemorheology are studied through use of spontaneously hypertensive rats. Experiments prove that the magnesium lithospermate B in physiological and pathological states both can dose-dependently improve kidney cortex microcirculation, and show that the kidney protective effect of the magnesium lithospermate B is realized through direct improvement of the kidney microcirculation, so that the salvianolate and the magnesium lithospermate B can be used for preparation of the drugs for the prevention and treatment of the kidney injures caused by the contrast agent. The application of the salvianolate in preparation of the kidney protective agent drugs has great clinical application value.
Hypoxemia is an abnormally low O 2  concentration in the blood. It can be lethal. When vital organs don't get enough O 2  to operate properly. A coronavirus infection can cause hypoxemia. Wherein this is probably the most common cause of coronavirus associated death. COVID-19 has killed millions of people to date. A method comprising the administration of a therapeutically effective amount of almitrine dimesylate to a subject with a coronavirus infection. To treat/ameliorate/reduce/prevent any coronavirus associated hypoxemia in the subject. Therein increasing the subject's chance of survival.
The present invention relates to a quick-acting capsule for aiding digestion and tonifying the kidney, and a preparing method thereof, which is a pure traditional Chinese medicine capsule preparation for treating stomach ulcers, duodenal ulcers and Type 2 diabetes. The prescription of the quick-acting capsule is composed of white peony alba, atractylodes macrocephala, cassia bark, fructus corni, bletilla tuber, prepared liauorice roots, Chinese yam, wolfberry fruit and galanga galangal fruit. The present invention follows the rules of Chinese medicine, such as integral regulation and treating both manifestation and root cause of diseases, and the quick-acting capsule enables yin and yang to be balanced, qi and blood to be filled, and organism functions to be normal. The preparing method comprises: after being selected and cleaned, the components are pulverized; after being filtered for more than 80 meshes, the pulverized substances are encapsulated. The administration method: the quick-acting capsule is taken with warm boiled water, 6 to 8 grains are taken per time, and the quick-acting capsule is taken for 2 to 3 times per day. Ten days form one period of treatment, and the obvious therapeutic effect can be obtained after 2 to 3 periods of treatment. The quick-acting capsule has no side effect, and raw food, cold food and irritative food are prohibited to be eaten when the medicine is taken.